Preventing deaths in persons with HIV/hepatitis B virus coinfection: A call to accelerate prevention and treatment efforts

Journal of Infectious Diseases

Volumn 205, Issue 2, 2012, Pages 166-168

  Peters, Philip J ^a   Marston, Barbara J ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MORTALITY; NOTE; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SCREENING; SEROCONVERSION; VACCINATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; COINFECTION; DISEASE PROGRESSION; FEMALE; HEPATITIS B, CHRONIC; HIV SEROPOSITIVITY; HUMANS; MALE;

EID: 84555177927     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir728     Document Type: Note

References (14)

1. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51-9. (Pubitemid 351920404)
2. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41. (Pubitemid 44232373)
3. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 8:402-9. (Pubitemid 46765200)
4. Chun HM, Roediger MP, Hullsiek KH, et al. Hepatitis B virus co-infection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2011; 205:185-93.
5. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and the risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-6. (Pubitemid 35472132)
6. Hoffman CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23:1881-9.
7. Dore GJ, Soriano V, Rockstroh J, et al. SMART INSIGHT Study Group. Frequent hepatitis B virus rebound among HIV-Hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010; 24:857-65.
8. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011; 54:801-7.
9. Lu PJ, Byrd KK, Murphy T, Winbaum C. Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S., 2009. Vaccine 2011; 29:7049-57.
10. World Health Organization. Blood safety and availability: Facts and figures from the 2007 blood safety survey. 2009. http://www.who. int/mediacentre/factsheets/fs279/en/index. html. Accessed 3 August 2011.
11. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Centers for Disease Control and Prevention, National Institutes of Health, HIV Medicine Associations of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations form the CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
12. Backus LI, Boothroyd DB, Phillips BR, et al. National quality forum performance measures for HIV/AIDS care: The department of veterans affairs' experience. Arch Intern Med 2010; 170:1239-46.
13. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT. HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat 2010; 17:879-86.
14. Matthews GV, Manzini P, Hu Z, et al. Impact of lamivudine on HIV and hepatitis B virus-related related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in South Africa. AIDS 2011; 25:1727-35.